In March 2016 Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Padlock to continue the development of medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complex formation in autoimmune diseases.
| Headquarters | Cambridge, MA |
| Website | www.padlocktx.com |
| @PadlockTx | |
| Pipeline | Preclinical |
| Partners | GlaxoSmithKline |